1. Introduction {#sec1-molecules-21-01065}
===============

*Erigeron floribundus* (Kunth) Sch. Bip. (Asteraceae) is an herbaceous plant, 1.5 m in height, with pubescent, lanceolate leaves and flowers in yellowish panicles. In Cameroon, it is commonly found as a weed along roadsides, and it is widely used in folk medicine to treat angina, female infertility, AIDS, dental pain, headache and various diseases of microbial and non-microbial origin \[[@B1-molecules-21-01065],[@B2-molecules-21-01065],[@B3-molecules-21-01065],[@B4-molecules-21-01065],[@B5-molecules-21-01065],[@B6-molecules-21-01065]\]. The leaf aqueous extract was proven to possess analgesic, anti-inflammatory and immunomodulatory activity \[[@B1-molecules-21-01065],[@B2-molecules-21-01065]\], the dichloromethane extract inhibition against dermatophytes \[[@B7-molecules-21-01065]\], and the leaf ethanolic and pentane extract antiplasmodial activity \[[@B8-molecules-21-01065]\]. Despite the interest in its bioactivity, the plant has received little phytochemical investigation. With regard to the essential oil, a previous work performed on Cameroonian plants showed sesquiterpene hydrocarbons as the major essential oil constituents \[[@B9-molecules-21-01065]\].

Given the wide use of the plant in traditional medicine, we evaluated the in vitro biological activities displayed by the essential oil obtained from the aerial parts of *E. floribundus*, namely the antioxidant, antiproliferative and antimicrobial activities that were investigated by 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2\'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS), ferric reducing antioxidant power (FRAP), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT), and agar disc diffusion and microdilution methods, respectively.

Because essential oils represent an interesting alternative approach against the occurrence of drug resistance in many infectious bacterial pathogens \[[@B10-molecules-21-01065]\] and fighting protozoan parasites \[[@B11-molecules-21-01065]\], we completed the work by investigating the activity of *E. floribundus* essential oil on nicotinate mononucleotide adenylyltransferase (NadD) and *Trypanosoma* *brucei*. Being natural in origin, essential oils and their components are believed to be environmentally favourable and user-friendly \[[@B12-molecules-21-01065]\]. Moreover, using innovative technologies, such as nanoencapsulation, many limits of their application in medicine (mainly low water solubility and stability, high volatility and side effects) could be overcome \[[@B13-molecules-21-01065]\].

NadD occupies a central position in bacterial NAD^+^ biosynthesis and is required for both de novo and salvage routes to generate NAD^+^ \[[@B14-molecules-21-01065],[@B15-molecules-21-01065],[@B16-molecules-21-01065]\]. NadD has been recognized as a promising new target for developing novel antibiotics due to its crucial role in synthesizing NAD^+^ \[[@B17-molecules-21-01065],[@B18-molecules-21-01065],[@B19-molecules-21-01065],[@B20-molecules-21-01065]\]. Another attractive aspect of targeting NadD is that it is highly conserved in the overwhelming majority of bacterial species including most pathogens. Therefore, drugs developed based on the inhibition of NadD have the potential of possessing wide-spectrum antibacterial activity.

*T. brucei* is a protozoan parasite responsible for Human African trypanosomiasis (HAT), a neglected disease also known as African sleeping sickness. HAT threatens primarily rural populations and is fatal unless treated. To date, there are a few drugs approved, although none of them are satisfactory, due to treatment failures and toxicity, and the parenteral administration that is inappropriate in settings with poor medical infrastructure. Therefore, there is an urgent need to improve HAT treatment by enhancing the oral administration and the discovery and development of cost-effective new drugs. Drug discovery efforts are nowadays directed towards natural products and medicinal plants represent a validated source for discovery of new lead compounds and standardized herbal medicines against trypanosomiasis \[[@B21-molecules-21-01065]\].

2. Results {#sec2-molecules-21-01065}
==========

2.1. Essential Oil Analysis {#sec2dot1-molecules-21-01065}
---------------------------

The composition of the essential oil hydrodistilled from the aerial parts of *E. floribundus* is reported in [Table 1](#molecules-21-01065-t001){ref-type="table"}. GC-MS analysis revealed that the essential oil had a complex chemical profile. Separation of volatile components was accomplished by using both polar and apolar columns (HP-5 MS and DB-WAX, respectively). A total of eighty-five constituents were identified accounting for 78.6% of the total composition. The main fraction of the essential oil was given by sesquiterpenes (60.4%), which were represented by oxygenated compounds (38.5%) and hydrocarbons (21.9%). Main representatives of these groups were caryophyllene oxide (12.4%) and spathulenol (12.2%), and (*E*)-β-farnesene (5.5%) and (*E*)-caryophyllene (4.2%), respectively. Monoterpenes constituted a minor part of the oil (13.0%), with hydrocarbons (11.5%) as the predominant components. Among them, limonene was the most representative (8.8%).

2.2. Cytotoxicity Assessment {#sec2dot2-molecules-21-01065}
----------------------------

General cell toxic effects of *E. floribundus* essential oil were evaluated using the MTT assay against the following human tumour cell lines: A375 human malignant melanoma cell line, MDA--MB 231 human breast adenocarcinoma cell line, and the HCT116 human colon carcinoma cell line. All cell lines were submitted to increasing concentrations of essential oil for 72 h. The results, collected in [Table 2](#molecules-21-01065-t002){ref-type="table"}, show that essential oil exhibited a significant growth inhibition against the examined human cancer cells and induced a concentration-dependent inhibitory effect in the dilutions ranging from 0.78--200 μg/mL. The IC~50~ values of the essential oil were 14.9, 20.8, and 22.5 μg/mL on HCT116, MDA--MB 231, and A375 cell lines, respectively.

2.3. Antimicrobial Activity {#sec2dot3-molecules-21-01065}
---------------------------

The essential oil of *E. floribundus* showed a good antimicrobial activity against *Staphylococcus aureus* using both disc diffusion and microdilution methods. The inhibition zone diameter (IZD) of almost 15 mm was indicative of a good activity. The corresponding minimum inhibitory concentration (MIC) was equal to 512 µg/mL ([Table 3](#molecules-21-01065-t003){ref-type="table"}). *S. aureus* is Gram-positive as well as *Enterococcus faecalis*. The latter was also included in the panel of tested bacteria but resulted in being less susceptible to the essential oil than *S. aureus* (IZD ≅ 9 mm) as confirmed by the much higher MIC value (4096 µg/mL). None of the Gram-negative bacterial species, namely *E. coli* and *P. aeruginosa*, were inhibited as assessed by the disc diffusion test. Therefore, antimicrobial susceptibility by the microdilution method was not investigated. In contrast, the yeast *C. albicans* growth was inhibited by the essential oil (IZD = 9 mm), which showed a minimum inhibitory concentration of 512 µg/mL by the microdilution method.

In view of the appreciable activity against *S. aureus*, an additional series of *S. aureus* clinical isolates from catheter-associated infections was selected to confirm the observation and to prove the extendibility of the antimicrobial activity of the essential oil beyond the reference strain ATCC 29213. Four isolates were selected based on their proven resistance towards oxacillin, the congener of methicillin \[[@B25-molecules-21-01065]\]. Hence, the four isolates were MRSA (methicillin-resistant *Staphylococcus aureus*). The MICs of essential oil against the clinical isolates were substantially superimposable to the one obtained against the reference strain, differing on average by one dilution (MIC ≅ 1024 µg/mL).

2.4. NadD Inhibition Analysis {#sec2dot4-molecules-21-01065}
-----------------------------

In our effort to explore natural compounds against nicotinate mononucleotide adenylyltransferase of the NadD family \[[@B26-molecules-21-01065],[@B27-molecules-21-01065]\], an essential enzyme of NAD biosynthesis in most bacteria, we evaluated the in vitro inhibition of *E. floribundus* essential oil against NadD from *S. aureus*. A preliminary single point inhibition test at the concentration of 80 μg/mL indicated a \~60% inhibition with no effect on the ubiquitous mammalian isoform NMNAT1 \[[@B28-molecules-21-01065]\]. Motivated by these results and by an observed broad-spectrum antimicrobial activity based on the diffusion IZD and MIC methods ([Table 3](#molecules-21-01065-t003){ref-type="table"}), we performed a dose-response inhibition using an oil concentration range of 5--160 μg/mL. The IC~50~ value of the essential oil for *Sa*NadD was 98 ± 11 μg/mL.

2.5. Antioxidant Activity {#sec2dot5-molecules-21-01065}
-------------------------

Despite the interest on the bioactivity of *E. floribundus* based on its uses in Cameroonian traditional medicine, we evaluated for the first time the antioxidant properties of the essential oil. Antioxidant activity is a complex process usually occurring through several mechanisms and its evaluation is often carried out by more than one test method \[[@B29-molecules-21-01065]\]. In this study, three antioxidant assays, namely DPPH free radical scavenging activity, ABTS radical cation scavenging activity, and ferric reducing antioxidant power (FRAP) were applied to evaluate the antioxidant properties of *E. floribundus* essential oil. As reported in [Table 4](#molecules-21-01065-t004){ref-type="table"}, the antioxidant activity determined by DPPH radical scavenging ability showed a value of 16.9 ± 0.1 μmol·(Trolox equivalents, TE)/g, with an IC~50~ value about 250 times higher than that of the positive control Trolox. Higher antioxidant activity was detected in the ABTS radical cation scavenging activity assay, with an average TE value of 85.5 ± 3.6 μmol·TE/g, and an IC~50~ value about 46 times higher than that of Trolox. It is noteworthy that the essential oil appeared to act as a good reducing agent (FRAP activity, TEAC = 411.9 ± 2.40 μmol·TE/g).

2.6. Inhibition of T. brucei Proliferation {#sec2dot6-molecules-21-01065}
------------------------------------------

A test of the *E. floribundus* oil against *T. brucei* proliferation showed that it was active at a much lower concentration than the Balb/3T3 mouse fibroblasts used as a control ([Table 5](#molecules-21-01065-t005){ref-type="table"}). When analyzing some of the components in the oil, we found that limonene had a six times higher activity against *T. brucei* than the oil itself (IC~50~ = 5.6 µg/mL) indicating that this is the major antitrypanosomal agent in *E. floribundus* oil. A calculation based on that limonene represents 8.8% of the oil and gives six times higher inhibition than the oil itself, which indicates that about half of the antitrypanosomal activity in the extract comes from limonene.

3. Discussion {#sec3-molecules-21-01065}
=============

Only a few papers dealing with the chemical composition of *E. floribundus* essential oil are available in literature. From a comparison of our data with those of Kuiate et al. \[[@B9-molecules-21-01065]\], we notice significant differences mainly from a quantitative point of view. In that study, the sesquiterpene hydrocarbons (39.9%--74.8%) were revealed as predominant over oxygenated compounds (7.0%--13.8%). The major representatives of these groups were the same but they occurred in different amounts, i.e., (*E*)-caryophyllene (8.5%--20.1%), (*E*)-β-farnesene (14.6%--24.1%), caryophyllene oxide (0.8%--5.4%) and spathulenol (1.0%--4.1%). Similarly, therein the monoterpenes hydrocarbons constituted a small fraction (5.2%--17.3%), with limonene as the most abundant compound (2.5%--11.4%). In addition, the presence of polyacetylenic constituents such as (*E*)-2-lachnophyllum ester (3.4%--26.8%) was reported. We assume that the above differences may depend on chemical polymorphism of the species and different periods of collection.

This work reports on the cytotoxic activity of *E. floribundus* essential oil. A compound or few compounds do not emerge from the composition of essential oil, which can be responsible for the cytotoxic activity on human tumor cell lines. Caryophyllene oxide provided evidence of potent cytotoxic activity against HepG2, AGS, HeLa, SNU-1, and SNU-16 cells, with IC~50~ values of 3.95, 12.6, 13.55, 16.79, and 27.39 μM, respectively \[[@B30-molecules-21-01065]\]. Spathulenol was reported weakly active on human epidermoid carcinoma (KB) and inactive on human breast cancer (BC) and human small cell lung cancer (NCIH187) cell lines \[[@B31-molecules-21-01065]\]. In addition, (*E*)-caryophyllene showed weak activity on the cell lines tested, with IC~50~ values ranging from 43.27 to 67.14 µg/mL for MDA--MB 231 and A375, respectively \[[@B32-molecules-21-01065]\]. Our previous study has demonstrated that limonene showed antiproliferative activity on the same cell lines as tested above with IC~50~ values ranging from 18.4 to 124.0 µg/mL, respectively \[[@B33-molecules-21-01065]\]. Limonene also induces apoptosis in LS174T colon cancer cells and in a lymphoma cell line (35 µg/mL, IC~50~) \[[@B34-molecules-21-01065],[@B35-molecules-21-01065]\]. Moreover, it shows antitumor activity on lung adenocarcinoma A549 (0.098 µL/mL, IC~50~) and hepatocarcinoma HepG2 cells (0.150 µL/mL, IC~50~) \[[@B36-molecules-21-01065]\]. To our knowledge, data reporting the cytotoxic activity of (*E*)-β-farnesene are missing. However, the concentrations of caryophyllene oxide (12.4%), spathulenol (12.2%), limonene (8.8%), (*E*)-β-farnesene (5.5%) and (*E*)-caryophyllene (4.2%) cannot fully explain the cytotoxic activity of *E. floribundus* essential oil, which means that some other minor compounds contributed to the activity of the essential oil

The antimicrobial activity investigation revealed that the essential oil is mainly active against the Gram-positive bacteria. A special emphasis might be put on the results obtained with *S. aureus*. Both the reference strain and the methicillin-resistant clinical isolates from invasive infections were susceptible to the essential oil. Given the importance of *S. aureus* in human medical microbiology and food microbiology, the result is an important outcome. To our knowledge, this is the first study reporting on the antibacterial activity of the essential oil from *E. floribundus*. On the contrary, one single previous study investigated its antifungal activity \[[@B9-molecules-21-01065]\]. Kuiate and coll. obtained a MIC equal to about 2 mg/mL against *C. albicans*, while in the present investigation the essential oil was inhibiting the yeast growth at 0.512 mg/mL. Considering the differences in composition outlined above, it can be possible to speculate on the putative constituents contributing to the anti-*Candida* activity. Candidates might be spathulenol and caryophyllene oxide. The hypothesis on the first is not sustained by the literature where spathulenol is described solely as possessing anti-inflammatory properties. Caryophyllene oxide was instead already investigated for its antifungal properties and is approved by the FDA as a food and cosmetic preservative \[[@B37-molecules-21-01065]\].

On the bacterial side, a hypothesis may be done with hexadecanoic acid: its concentration in the oil (2.5%) could be compatible with its reported anti-staphylococcal activity \[[@B38-molecules-21-01065]\].

Of note, the in vitro inhibition of NadD focusing on isolating individual components of the above oil mixtures that retain both such activities.

From radical scavenging activity assays (i.e., DPPH and ABTS, [Table 4](#molecules-21-01065-t004){ref-type="table"}), we found that the *E. floribundus* essential oil displayed a weak activity. The chemical profile of the oil, with spathulenol (12.2%), caryophyllene oxide (12.4%) and limonene (8.8%) as the major components, may partially justify the low inhibition on these radicals \[[@B39-molecules-21-01065],[@B40-molecules-21-01065],[@B41-molecules-21-01065]\]. On the other hand, the high value of reducing power indicated that the essential oil components are able to act as electron donors and reduce the oxidized intermediate of lipid peroxidation so that they can act as primary and secondary antioxidants. Further studies are required to confirm the potential of this oil as reducing agent.

To the best of our knowledge, this is the first report on trypanocidal activity of the essential oil of *E. floribundus*, which further confirms the medical value of the plant. With an IC~50~ value of 5.6 µg/mL the lipophilic hydrocarbon limonene showed a quite remarkable trypanocidal activity against *T. brucei*. Additionally, limonene did not show significant toxicity in Balb/3T3 mouse fibroblasts (IC~50~ \> 100 µg/mL) and exhibited a favourable selectivity index (SI \> 17.85). Its trypanocidal activity could be explained by the high degree of unsaturation (two double bonds) in its chemical structure. In addition, its exocyclic methylene group can easily react with SH groups in proteins (e.g., trypanothione synthase), thus enhancing its bioactivity by exposing the parasite to oxidative damage \[[@B42-molecules-21-01065]\]. However, further investigations are required in order to clarify the mechanism of action of essential oil and limonene itself and to evaluate their therapeutic values for trypanosomiasis infections.

4. Materials and Methods {#sec4-molecules-21-01065}
========================

4.1. Plant Materials {#sec4dot1-molecules-21-01065}
--------------------

Aerial parts of *E. floribundus* were harvested in Dschang, West Province of Cameroon (1450 m a.s.l.) in February 2013. The plant was identified at the Cameroon National Herbarium (Yaoundé), where a voucher specimen was deposited (5619SRF/Cam). Plant material was dried at room temperature in the shade for one week before undergoing total extraction.

4.2. Hydrodistillation {#sec4dot2-molecules-21-01065}
----------------------

The dry aerial parts (500 g) were reduced into small pieces, then subjected to hydrodistillation in a Clevenger-type apparatus for 4 h using 6 L of deionized water. The essential oil yield (0.2%, *n* = 3) was estimated on a dry-weight basis (*w/w*). Once obtained, the oil was dried (Na~2~SO~4~), transferred into an amber glass flask, and kept at −20 °C before chemical analysis and biological experiments.

4.3. Chemicals {#sec4dot3-molecules-21-01065}
--------------

For identification of volatiles the following analytical standards were purchased from Sigma-Aldrich (Milan, Italy): α-pinene, β-pinene, *p*-cymene, limonene, γ-terpinene, linalool, *trans*-pinocarveol, terpinen-4-ol, α-terpineol, myrtenol, nerol, carvone, geraniol, geranial, eugenol, (*E*)-caryophyllene, α-humulene, (*E*)-β-farnesene, (*E*)-β-ionone, (*E*)-nerolidol, caryophyllene oxide, *n*-pentacosane, *n*-heptacosane; (*E*)-Phytol was previously isolated from *Onosma echioides* \[[@B43-molecules-21-01065]\]. For retention-index (RI) determination, a mixture of hydrocarbons, ranging from octane (C~8~) to triacontane (C~30~) (Supelco, Bellefonte, PA, USA) was used and run under the experimental conditions reported below. All compounds were of analytical standard grade. Analytical-grade hexane solvent was purchased from Carlo Erba (Milan, Italy); it was successively distilled through a Vigreux column before use.

4.4. Chemical Analysis of Essential Oil {#sec4dot4-molecules-21-01065}
---------------------------------------

GC-MS Analysis was performed on an Agilent 6890N gas chromatograph (Santa Clara, CA, USA) coupled to a 5973N mass spectrometer using two different capillary columns: a HP-5 MS column (5% phenylmethylpolysiloxane, 30 m, 0.25 mm i.d., 0.1-mm film thickness; J & W Scientific (Folsom, CA, USA), and a DB-WAX column (polyethylene glycol; 30 m, 0.25 mm i.d., 0.25-mm film thickness; J & W Scientific,). The oven temperature program was the following: 5 min at 60 °C, subsequently 4 °C/min up to 220 °C, then 11 °C/min up to 280 °C, held for 15 min, for a total run of 65 min. Injector and detector temperatures were 280 °C. He was used as the carrier gas, at a flow rate of 1 mL/min. Split ratio, 1:50; acquisition mass range, *m/z* 29--400. All mass spectra were acquired in electron--impact (EI) mode with an ionization voltage of 70 eV. Oil samples were diluted to 1:100 in *n*-hexane, and the volume injected was 2 µL. Whenever possible, the essential oil constituents were identified by co-injection with authentic standards. Otherwise, the peak assignment was carried out according to the recommendations of the International Organization of the Flavour Industry (<http://www.iofi.org/>), i.e., by the interactive combination of chromatographic linear retention indices that were consistent with those reported in the literature \[[@B22-molecules-21-01065],[@B23-molecules-21-01065],[@B24-molecules-21-01065]\] for apolar and polar stationary phases, and MS data consisting in computer matching with the WILEY275, NIST 08, ADAMS, FFNSC2 and home-made (based on the analysis of reference oils and commercially available standards) libraries. Quantification of essential oil components was achieved by peak-area internal normalisation without using correction factors.

4.5. Antimicrobial Activity {#sec4dot5-molecules-21-01065}
---------------------------

The essential oil of *E. floribundus* was tested against a panel of reference bacterial and yeast species including *Staphylococcus aureus* ATCC 25923, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, *Enterococcus faecalis* ATCC 29212, *Candida albicans* ATCC 24433. Extension of the investigation on *S. aureus* was accomplished using four additional *S. aureus* clinical isolates ([Table 3](#molecules-21-01065-t003){ref-type="table"}) that were resistant to methicillin and maintained in the collection of the Microbiology Unit of the School of Pharmacy at the University of Camerino \[[@B25-molecules-21-01065]\]. Bacterial strains were cultured overnight at 37 °C in blood agar plates. *C. albicans* was grown in Sabouraud Dextrose Agar. Tests by the paper disc diffusion method were performed following the Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@B44-molecules-21-01065]\]. Briefly, a suspension of the tested microorganism (1--2 × 10^8^ cells per mL in saline-10^6^ per mL for Candida) was spread on the solid media plates using a sterile cotton swab. Sterile paper discs (6 mm in diameter) were placed on the surface of inoculated plates and spotted with 10 µL of either the essential oil or 1 mg of extract dissolved in DMSO. The plates were incubated 24 h at 35 ± 1 °C (48 h for *C. albicans*). The diameters of zone inhibition (including the 6 mm disc) were measured with a gauge. A reading of more than 6 mm indicated growth inhibition. No zone inhibition was observed using DMSO alone. Ciprofloxacin (5 μg disc) and Nystatin (100 Units disc) were used as reference antimicrobials against bacteria and fungi, respectively. Each test was repeated at least twice. Antibiotic susceptibility testing by the microdilution method was performed following the international guidelines \[[@B44-molecules-21-01065]\]. Briefly, two-fold serial dilutions of each mixture in Cation Adjusted Mueller Hinton Broth for bacteria and Roswell Park Memorial Institute (RPMI) 1640 for *Candida* were set in 96-well plates starting from 2048 mg/L. An equal volume of the microbial inoculum (10^6^ cfu/mL), obtained by direct colony suspension of an overnight culture, was added to each well of the microtiter plate containing 0.1 mL of the serially diluted test oil/extract. After incubation for 18--24 h at 35 °C, in normal atmosphere, Minimum Inhibitory Concentrations (MICs) were defined as the lowest concentration of compound able to inhibit the growth of the microorganisms. All tests were done in triplicate.

4.6. Antioxidant Activity {#sec4dot6-molecules-21-01065}
-------------------------

The antioxidant activity of *E. floribundus* essential oil was measured by using different radical generating systems (DPPH, ABTS and FRAP assay) to assess the free radical scavenging and reducing properties of the oil \[[@B45-molecules-21-01065]\]. All the experiments were conducted in a 96-well microplate assay according to the method of Srinivasan et al. \[[@B46-molecules-21-01065]\], for DPPH assay and following previously-described protocols by Re et al. \[[@B47-molecules-21-01065]\], for measuring the total radical scavenging capacity on ABTS radical. The ferric reducing antioxidant power (FRAP assay) was carried out according to the procedure described by Müller et al. \[[@B48-molecules-21-01065]\], by monitoring the reduction of Fe^3+^-tripyridyl triazine (TPTZ) to blue-coloured Fe^2+^-TPTZ. The ability of *E. floribundus* essential oil to scavenge the different radicals in all three assays was compared to Trolox used as standard. Results as tocopherol-equivalent antioxidant capacity (TEAC) were expressed in μM Trolox equivalents (TE)/g of essential oil.

4.7. Cytotoxic Activity on Tumor Cells {#sec4dot7-molecules-21-01065}
--------------------------------------

A375 (human malignant melanoma cells) and MDA--MB 231 cells (human breast adenocarcinoma cells) were cultured in Dulbecco′s Modified Eagle′s Medium (DMEM) with 2 mM [l]{.smallcaps}-glutamine, 100 IU/mL penicillin, 100 µg/mL streptomycin, and supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS). HCT116 cells (human colon carcinoma cells), were cultured in RPMI1640 medium with 2 mM [l]{.smallcaps}-glutamine, 100 IU/mL penicillin, 100 μg/mL streptomycin, and supplemented with 10% HI-FBS. Cells were cultured in a humidified atmosphere at 37 °C in presence of 5% CO~2~. The MTT assay was used as a relative measure of cell viability. Cell-viability assays were carried out as described \[[@B49-molecules-21-01065]\]. Briefly, cells were seeded at the density of 2 × 10^4^ cells/mL. After 24 h, samples were exposed to different concentrations of essential oil (0.78--200 μg/mL). Cells were incubated for 72 h in a humidified atmosphere of 5% CO~2~ at 37 °C. Cisplatin was used as the positive control (0.05--20 µg/mL). At the end of incubation, each well received 10 µL of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) (5 mg/mL in phosphate-buffered saline, PBS) and the plates were incubated for 4 h at 37 °C. The extent of MTT reduction was measured spectrophotometrically at 540 nm using a Titertek Multiscan microElisa (Labsystems, Helsinki, Finland. Experiments were conducted in triplicate. Cytotoxicity is expressed as the concentration of compound inhibiting cell growth by 50% (IC~50~). The IC~50~ values were determined with the GraphPad Prism 4 computer program (GraphPad Software, San Diego, CA, USA).

4.8. Enzyme Inhibition Assay {#sec4dot8-molecules-21-01065}
----------------------------

Recombinant *S. aureus* NadD, available in our laboratory, was used as a representative bacterial target of the NadD enzyme family. Previous reports, indeed, have proven that this target enzyme is highly conserved in bacteria \[[@B17-molecules-21-01065]\] and small molecule inhibitors may be simultaneously active on NadDs from distant species such as *S. aureus* and *M. tuberculosis* \[[@B50-molecules-21-01065]\]. Murine NMNAT1 was chosen as the functionally equivalent mammalian enzyme \[[@B51-molecules-21-01065]\].

The enzyme inhibition assay setup for the bacterial enzyme and the mammalian counter target is described in detail in Vitali et al. \[[@B27-molecules-21-01065]\]. Briefly, enzyme rates and inhibition were measured by an established endpoint assay based on the detection at 620 nm of the phosphate byproduct formed \[[@B17-molecules-21-01065]\]. A continuous assay based on detection at 340 nm of the reduced form of nicotinamide adenin dinucleotide (NADH) formed was used as an alternate assay \[[@B52-molecules-21-01065]\].

4.9. T. brucei and Mammalian Cell Culture {#sec4dot9-molecules-21-01065}
-----------------------------------------

*T. brucei* BSFs (TC221) were cultured at 37 °C with 5% CO~2~ in HMI-9 medium supplemented with 10% (*v/v*) heat-inactivated fetal bovine serum (Thermo Fisher Scientific \[Gibco\], Waltham, MA, USA). Mouse BALB/3T3 fibroblast (ATCC no CCL-163) were cultivated at 37 °C and 5% CO~2~ in Dulbecco′s modified Eagle′s medium (Sigma-Aldrich), supplemented with 10% (*v/v*) heat-inactivated fetal bovine serum, glutamine (0.584 g/L) and 10 mL/L 100× penicillin-streptomycin (Thermo Fisher Scientific \[Gibco\]) \[[@B53-molecules-21-01065]\].

4.10. Growth Inhibition Assay on T. brucei and Balb/3T3 Cells {#sec4dot10-molecules-21-01065}
-------------------------------------------------------------

The essential oil was dissolved in dimethyl sulfoxide (DMSO). It was serially diluted with growth medium to concentrations ranging from 2 × 10^−5^ to 200 µg/mL in 96-well microtiter plates (100 µL/well). Subsequently, 100 µL of *T. brucei* or mammalian cell culture was added to each well (20,000 cells/well). After 48 h incubation, the plates were treated for 24 h with 20 µL of resazurine (Sigma-Aldrich). They were subsequently quantified by fluorescence (540 nm excitation and 590 nm emission) using an Infinite M200 microplate reader (Tecan Group Ltd., Männedorf, Switzerland). The IC~50~ values were calculated by fitting the data to a log inhibitor vs. response curve (variable slope, four parameters) using the GraphPad Prism version 5.04 software.

5. Conclusions {#sec5-molecules-21-01065}
==============

The present work provides new insights into the phytochemical and biological properties of *E. floribundus*. The essential oil of this plant revealed a good potential as bacterial NadD inhibitor, thus being a promising candidate for antibiotic formulations. The exhibited trypanocidal activity, on one hand, confirmed partially the traditional use in the treatment of protozoal diseases, and on the other hand, makes it a potential candidate for standardized herbal medicines against trypanosomiasis that are highly requested in developing countries with poor medical infrastructure and difficult access to conventional medical treatments.
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Composition of the essential oil hydrodistilled from the aerial parts of *Erigeron floribundus*.

  N.   Component ^1^                              RI Calc. ^2^   RI Lit. ^3^   \% ^4^   ID ^5^            
  ---- ------------------------------------------ -------------- ------------- -------- -------- -------- --------
  1    butyl methyl ketone                        780            1088          786      1088     tr ^6^   RI, MS
  2    hexanal                                    792            1024          801      1024     0.1      RI, MS
  3    (3*E*)-hexenol                             844            1371          844      1371     0.2      RI, MS
  4    *n*-hexanol                                858            1363          863      1363     0.1      RI, MS
  5    1-(2-methyl-2-cyclopenten-1-yl)-ethanone   871                                            tr       MS
  6    α-pinene                                   921            1026          932      1026     0.2      Std
  7    sabinene                                   960            1125          969      1125     tr       RI, MS
  8    β-pinene                                   962            1112          974      1112     2.1      Std
  9    myrcene                                    983            1167          988      1165     0.1      Std
  10   2-pentyl furan                             983            1231          984      1231     0.1      RI, MS
  11   *p*-cymene                                 1017           1271          1020     1272     tr       Std
  12   limonene                                   1020           1199          1024     1199     8.8      Std
  13   (*E*)-β-ocimene                            1042           1255          1044     1255     0.1      RI, MS
  14   γ-terpinene                                1051           1253          1054     1255     tr       Std
  15   terpinolene                                1080           1283          1086     1282     tr       RI, MS
  16   linalool                                   1096           1555          1095     1556     0.1      Std
  17   *n*-nonanal                                1102           1393          1100     1395     tr       RI, MS
  18   (*E*)-4,8-dimethyl-1,3,7-nonatriene        1112                                           tr       MS
  19   *trans*-*p*-mentha-2,8-dien-1-ol           1114                         1119              tr       RI, MS
  20   *trans*-pinocarveol                        1129           1656          1135     1657     0.1      Std
  21   nerol oxide                                1150                         1154              tr       RI, MS
  22   pinocarvone                                1153           1563          1160     1565     0.1      RI, MS
  23   lavandulol                                 1163           1686          1170     1686     0.1      RI, MS
  24   terpinen-4-ol                              1169           1600          1174     1600     0.1      Std
  25   *trans*-isocarveol                         1180           1838          1175              tr       RI, MS
  26   α-terpineol                                1182           1688          1186     1690     0.2      Std
  27   myrtenal                                   1188           1648          1195     1648     0.1      RI, MS
  28   myrtenol                                   1188           1794          1194     1794     0.1      Std
  29   β-cyclocitral                              1212                         1217              0.1      RI, MS
  30   nerol                                      1223           1840          1227     1838     0.4      Std
  31   carvone                                    1236           1744          1239     1745     0.1      Std
  32   geraniol                                   1253           1850          1249     1852     tr       Std
  33   perilla aldehyde                           1265           1783          1265     1784     tr       RI, MS
  34   geranial                                   1268           1730          1264     1730     tr       Std
  35   perilla alcohol                            1291           2028          1290     2029     0.1      RI, MS
  36   silphiperfol-5-ene                         1310           1421          1326              0.3      RI, MS
  37   α-cubebene                                 1338           1457          1345              0.1      RI, MS
  38   eugenol                                    1351           2164          1356     2167     0.1      Std
  39   α-copaene                                  1362           1488          1374     1488     0.7      RI, MS
  40   modheph-2-ene                              1363           1516          1377              0.7      RI, MS
  41   α-isocomene                                1370           1529          1377              0.5      RI, MS
  42   β-cubebene                                 1378                         1379              0.2      RI, MS
  43   β-elemene                                  1380                         1389              0.2      RI, MS
  44   β-isocomene                                1387                         1407              0.4      RI, MS
  45   (*Z*)-caryophyllene                        1392           1570          1408              2.3      RI, MS
  46   (*E*)-caryophyllene                        1403           1590          1417     1585     4.2      Std
  47   β-copaene                                  1414           1535          1430              0.4      RI, MS
  48   β-gurjunene                                1422                         1431              0.1      RI, MS
  49   α-*trans*-bergamotene                      1425           1583          1432     1586     2.1      RI, MS
  50   α-humulene                                 1437           1663          1452     1665     1.0      Std
  51   geranyl acetone                            1447                         1453              0.1      RI, MS
  52   (*E*)-β-farnesene                          1451           1745          1454     1745     5.5      Std
  53   γ-muurolene                                1464           1683          1478              0.4      RI, MS
  54   germacrene D                               1466           1701          1484     1700     0.1      RI, MS
  55   β-selinene                                 1470                         1489              0.1      RI, MS
  56   *ar*-curcumene                             1473           1770          1479     1769     1.0      RI, MS
  57   (*E*)-β-ionone                             1476           1934          1487     1936     0.1      Std
  58   *cis*-β-guaiene                            1481                         1492              0.2      RI, MS
  59   γ-curcumene                                1481           1673          1481              0.2      RI, MS
  60   α-muurolene                                1487           1719          1500              0.2      RI, MS
  61   modhephen-8-β-ol                           1492                         1513              0.2      RI, MS
  62   γ-cadinene                                 1499                         1513              0.3      RI, MS
  63   δ-cadinene                                 1511           1753          1522     1752     0.5      RI, MS
  64   α-calacorene                               1528           1907          1544              0.1      RI, MS
  65   (*E*)-nerolidol                            1557           2048          1561     2049     2.1      Std
  66   spathulenol                                1564           2127          1577     2132     12.2     RI, MS
  67   caryophyllene oxide                        1567           1977          1582     1983     12.4     Std
  68   salvial-4(14)-en-1-one                     1577           2000          1594              0.8      RI, MS
  69   humulene epoxide II                        1591           2034          1608     2040     1.7      RI, MS
  70   caryophylla-4(12),8(13)-dien-5α-ol         1615                         1639              0.6      RI, MS
  71   caryophylla-4(12),8(13)-dien-5β-ol         1619                         1639              1.0      RI, MS
  72   *tau*-cadinol                              1626           2126          1625     2125     1.0      RI, MS
  73   muurola-4,10(14)-dien-1-beta-ol            1637                         1630              1.0      RI, MS
  74   α-cadinol                                  1640           2232          1652     2232     1.0      RI, MS
  75   14-hydroxy-9-*epi*-(*E*)-caryophyllene     1656                         1668              2.1      RI, MS
  76   germacra-4(15),5,10(14)-trien-1-α-ol       1669                         1685              2.1      RI, MS
  77   pentadecanal                               1706           2041          1705     2041     0.6      RI, MS
  78   β-bisabolenol                              1776                         1785              0.2      RI, MS
  79   14-hydroxy-δ-cadinene                      1787                         1788              0.3      RI, MS
  80   neophytadiene                              1831                                           0.2      MS
  81   2-pentadecanone, 6,10,14-trimethyl-        1837           2131          1838     2131     0.3      RI, MS
  82   hexadecanoic acid                          1962           2918          1959     2917     2.5      RI, MS
  83   (*E*)-phytol                               2094           2624          2096     2622     0.7      Std
  84   *n*-pentacosane                            2500           2500          2500     2500     tr       Std
  85   *n*-heptacosane                            2700           2700          2700     2700     tr       Std
       Total identified (%)                                                                      78.6     
       Grouped compounds                                                                                  
       Monoterpene hydrocarbons                                                                  11.5     
       Oxygenated monoterpenes                                                                   1.5      
       Sesquiterpene hydrocarbons                                                                21.9     
       Oxygenated sesquiterpenes                                                                 38.5     
       Others                                                                                    5.2      

^1^ Compounds are listed in order of their elution from an HP-5MS column. Their nomenclature was in accordance with Adams \[[@B22-molecules-21-01065]\]. ^2^ Linear retention index on HP-5MS and DB-Wax column, experimentally determined using homologous series of C8--C30 alkanes. ^3^ Linear retention index taken from Adams \[[@B22-molecules-21-01065]\] and/or NIST08 \[[@B23-molecules-21-01065]\] for apolar columns, and from FFNSC2 \[[@B24-molecules-21-01065]\] and/or NIST08 for polar columns. ^4^ Percentage values are means of three determinations with an RSD% for the main components below 5% in all cases. ^5^ Identification methods: std, based on comparison with authentic compounds; MS based on comparison with Wiley. ADAMS and NIST08 MS database; RI, based on comparison of RI with those reported in ADAMS and NIST08. ^6^ tr, traces (mean value below 0.1%).

molecules-21-01065-t002_Table 2

###### 

In vitro growth inhibition of tumor cells by *Erigeron floribundus* essential oil.

                     Cell Line (IC~50~ µg/mL) ^1^                  
  ------------------ ------------------------------ -------------- --------------
  Essential oil      22.5                           20.8           14.9
  95% C.I. ^5^       20.6--24.6                     16.82--25.77   13.10--17.00
  Positive control                                                 
  Cisplatin          0.5                            2.5            2.5
  95% C.I.           0.4--0.5                       2.0--3.0       2.2--2.9

^1^ IC~50~ = the concentration of compound that affords a 50% reduction in cell growth (after 72 h of incubation). ^2^ Human malignant melanoma cell line. ^3^ Human breast adenocarcinoma cell line. ^4^ Human colon carcinoma cell line. ^5^ C.I. Confidence interval.

molecules-21-01065-t003_Table 3

###### 

In vitro antimicrobial activity of *Erigeron floribundus* essential oil.

  Species           Strain       Essential Oil   Reference Antibiotic ^1^                  
  ----------------- ------------ --------------- -------------------------- -------------- --------
  *S. aureus*       ATCC 29213   14.3 ± 0.6      512                        20.67 ± 1.15   0.25
  MRSA ^4^ -19                   1024--2048                                                
  MRSA-42                        512--1024                                                 
  MRSA-75                        512--1024                                                 
  MRSA-101                       512--1024                                                 
  *E. faecalis*     ATCC 29212   8.7 ± 0.6       4096                       24.0 ± 2.6     0.5--1
  *E. coli*         ATCC 25922   n.a. ^5^        N.D. ^6^                   19.7 ± 0.6     0.016
  *P. aeruginosa*   ATCC 27853   n.a.            N.D.                       21.7 ± 0.6     0.5
  *C. albicans*     ATCC 24433   9.0 ± 1.0       512                        16.33 ± 0.58   4.0

^1^ Ciprofloxacin for Gram-positive species, gentamicin for Gram-negative ones; nystatin for *C. albicans*. ^2^ IZD, inhibition zone diameter. Each value is an average of three independent experiments with standard errors indicated. ^3^ MIC; minimum inhibitory concentration. ^4^ MRSA, Methicillin-Resistant *Staphylococcus aureus.* ^5^ n.a., no activity. ^6^ N.D., not determined.

molecules-21-01065-t004_Table 4

###### 

Antioxidant activity of *Erigeron floribundus* essential oil.

                         DPPH         ABTS          FRAP                      
  ---------------------- ------------ ------------- ------------ ------------ --------------
  *E. floribundus* oil   16.9 ± 0.1   356.7 ± 7.1   85.5 ± 3.6   74.9 ± 3.2   411.9 ± 2.40
  Trolox                              1.51 ± 0.04                1.6 ± 0.01   

^1^ TEAC: Trolox equivalent (TE) antioxidant concentration. ^2^ IC~50~: The concentration giving a reduction of 50%. Each value is an average of three independent experiments with standard errors indicated.

molecules-21-01065-t005_Table 5

###### 

Inhibition of *T. brucei* and Balb/3T3 fibroblast proliferation.

                         *T. brucei* IC~50~ ^1^ (μg/mL)   Balb/3T3 IC~50~ ^1^ (μg/mL)   Selectivity Index (SI)
  ---------------------- -------------------------------- ----------------------------- ------------------------
  *E. floribundus* oil   33.5 ± 2.7                       \>200                         \>5.97
  Carophyllene oxide     \>200                            N.D.                          
  Limonene               5.6 ± 1.6                        \>100                         \>17.85

^1^ Each value is an average of three independent experiments with standard errors indicated.
